Compound: Savolitinib
SMILES: n1c(-c2cnn(c2)C)cnc3c1n(nn3)[C@H](c4cn5c(ncc5)cc4)C
InChIKey: XYDNMOZJKOGZLS-NSHDSACASA-N
Synonyms: Savolitinib, Volitinib, 1313725-88-0, HMPL-504, AZD-6094, AZD6094, HMPL504, savolitinibum, 2A2DA6857R, AZD 6094, 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine, DTXSID801111016, 1-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine, 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-, 1-((1S)-1-Imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo(4,5-b)pyrazine, 3-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-5-(1-methylpyrazol-4-yl)triazolo(4,5-b)pyrazine, RefChem:884623, DTXCID301542632, Savolitinib [INN], Orpathys, (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine, Volitinib(Savolitinib), MFCD28359096, HMPL 504, CHEMBL3334567, 4-{1-[(1S)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyrazole, UNII-2A2DA6857R, C17H15N9, Volitinib; 1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine; AZD 6094; HM 5016504; HMPL 504, Volitinib dihydrochloride, AZD6094 dihydrochloride, Savolitinib [USAN:INN], Savolitinib dihydrochloride, SAVOLITINIB [USAN], HMPL-504 dihydrochloride, Savolitinib (AZD6094), SAVOLITINIB [WHO-DD], Savolitinib (JAN/USAN/INN), GTPL9918, orb1296129, SCHEMBL12489208, SCHEMBL29517102, EX-A845, CHEBI:231369, GLXC-90352, AZD6094, HMPL-504, BDBM50023342, EBC-13169, NSC782121, NSC800966, s7674, AKOS030526403, Savolitinib(AZD6094, HMPL-504), CCG-267976, DB12048, NSC-782121, NSC-800966, compound 28 [PMID: 25148209], NCGC00475727-01, AC-35267, AS-35250, BV160378, HY-15959, HM 5016504, HM-5016504, NS00073442, Savolitinib;Volitinib;HMPL-504;AZD-6094, D11139, EN300-7482485, BRD-K98028353-001-01-0, Q27254463, Z3041529961, (S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine dihydrochloride, 1-((S)-1-(IMIDAZO(1,2-A)PYRIDIN-6-YL)ETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-(1,2,3)-TRIAZOLO(4,5-B)PYRAZINE, 1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine
Theoretical properties:
molecular_formula: C17H15N9
molecular_weight: 345.4 g/mol
exact_mass: 345.14504152 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 3
heavy_atom_count: 26
topological_polar_surface_area: 91.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Savolitinib is a member of the class of triazolopyrazines that is 1H-[1,2,3]triazolo[4,5-b]pyrazine substituted by (1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl and 1-methyl-1H-pyrazol-4-yl groups at positions 1 and 6, respectively. It is a highly selective MET tyrosine kinase inhibitor that is approved in China for advanced NSCLC with MET exon 14 skipping mutations. It has a role as an antineoplastic agent and a c-Met tyrosine kinase inhibitor. It is a member of pyrazoles, an imidazopyridine and a triazolopyrazine.
chebi: A member of the class of triazolopyrazines that is 1<em>H</em>-[1,2,3]triazolo[4,5-<em>b</em>]pyrazine substituted by (1<i>S</i>)-1-(imidazo[1,2-<em>a</em>]pyridin-6-yl)ethyl and 1-methyl-1<em>H</em>-pyrazol-4-yl groups at positions 1 and 6, respectively. It is a highly selective MET tyrosine kinase inhibitor that is approved in China for advanced NSCLC with MET exon 14 skipping mutations.
chembl: SAVOLITINIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. It has been given conditional approval for these indication in China.